Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUNCTION-DMD
NCT07429240Phase 2Recruiting
- Sponsor
- Precision BioSciences, Inc.
- Start
- Apr 2026
- Primary completion
- Nov 2029
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of PBGENE-DMD in Duchenne muscular dystrophy (DMD), sponsored by Precision BioSciences, Inc.. Started Apr 2026; status: recruiting.
02
Drugs
PBGENE-DMD
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07429240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429240.